EuroPCR 2021 | A New Meta-Analysis Challenges the ISCHEMIA Trial

This paper suggests that patients with stable coronary artery disease who undergo elective coronary revascularization find a long-term benefit in terms of cardiac death compared with patients who receive medical treatment alone.

These findings, presented at EuroPCR 2021 and simultaneously published in the European Heart Journal, challenge the results from the ISCHEMIA trial.

Researchers state that the benefit in mortality could be directly linked to follow-up time. The longer the follow-up time, the greater the benefit observed in cardiac mortality and infarction with angioplasty or surgery.

Any doubts raised by this new meta-analysis will be answered relatively quickly. Researchers from the ISCHEMIA trial announced ISCHEMIA-EXTEND, which will add five more years of follow-up to the original study for over 5000 patients.

It is only a matter of time before we know the long-term all-cause mortality rates (approximately 10 years).

This meta-analysis included 25 studies and almost 20,000 patients with stable coronary artery disease who underwent elective revascularization vs. medical treatment.


Read also: EuroPCR 2021 | CELEBRATE-02: Novel Glycoprotein IIb/IIIa Inhibitor for ST-Segment Elevation Infarction.


Among the 25 studies, some are older—like MASS-1, RITA-2, and COURAGE—, while some are more recent—like ORBITA, FAME 2, and, of course, ISCHEMIA.

A 21% reduction in the risk of cardiac death (risk ratio [RR]: 0.79; 95% confidence interval [CI]: 0.67-0.93) was observed in patients who underwent revascularization vs. those who continued receiving medical treatment alone.

For each additional four years of follow-up, there was a 19% reduction in the risk of dying from cardiac causes among patients who underwent revascularization.

All-cause mortality was similar between both treatment strategies (RR: 0.94: 95% CI: 0.87-1.01). This is one of the reasons why researchers from ISCHEMIA-EXTEND decided on this endpoint instead of cardiac death.


Read also: AHA 2019 | ISCHEMIA: The Invasive Approach (PCI or Surgery) Results Similar to Optimal Medical Treatment.


This might be a heated argument in the future: does revascularization reduce mortality or does it just choose a non-cardiac death?

revascularización-electiva

Original Title: Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis.

Reference: Navarese EP et al. Eur Heart J. 2021; Epub ahead of print. doi:10.1093/eurheartj/ehab246.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....